Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer

Mirzaei-Parsa, Mohamad Javad; Najafabadi, Mohammad Reza H.; Haeri, Azadeh; Zahmatkeshan, Masoumeh; Ebrahimi, Soltan Ahmad; Adel, Moein

doi:10.1007/s12282-019-01014-w

Cited by 32 publications

(12 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The niosomal bilayer allows for drug trafficking within the body, protecting the drug from premature degradation, and directing therapeutic payloads to their site of need, thus reducing the unwanted off-target effects, which result in detrimental patient side effects. Not only are niosomes biocompatible, but they are also biodegradable; they exist at the nanometer scale, representing a high potential choice for targeted cancer therapy [12]. Some cancer cell types possess positive estrogen and progesterone receptors, growing faster in estrogen and progesterone environments, respectively.…”

Section: Introductionmentioning

confidence: 99%

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

et al. 2021

View full text Add to dashboard Cite

Breast cancer is one of the most prevalent causes of cancer mortality in women. In order to increase patient prognosis and survival rates, new technologies are urgently required to deliver therapeutics in a more effective and efficient manner. Niosome nanoparticles have been recently employed as therapeutic platforms capable of loading and carrying drugs within their core for both mono and combination therapy. Here, niosome-based nanoscale carriers were investigated as a targeted delivery system for breast cancer therapy. The platform developed consists of niosomes loaded with letrozole and cyclophosphamide (NLC) and surface-functionalized with a folic-acid-targeting moiety (NLCPFA). Drug release from the formulated particles exhibited pH-sensitive properties in which the niosome showed low and high release in physiological and cancerous conditions, respectively. The results revealed a synergic effect in cytotoxicity by co-loading letrozole and cyclophosphamide with an efficacy increment in NLCPFA use in comparison with NLC. The NLCPFA resulted in the greatest drug internalization compared to the non-targeted formulation and the free drug. Additionally, downregulation of cyclin-D, cyclin-E, MMP-2, and MMP-9 and upregulating the expression of caspase-3 and caspase-9 genes were observed more prominently in the nanoformulation (particularly for NLCPFA) compared to the free drug. This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, the clinical application of intra-tumoral drugs has slowed down recently due to its limitations, especially since primary tumors are easier to remove by surgery. However, for the treatment of metastatic or inoperable diseases, systemic treatment is necessary (49).…”

Section: Discussionmentioning

confidence: 99%

Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2

et al. 2020

View full text Add to dashboard Cite

Anaplastic thyroid carcinoma (ATC) is a highly aggressive tumor with a poor prognosis and a low median survival rate because of insufficient effective therapeutic modalities. Recently, mesoporous silica nanoparticles (MSNs) as a green non-toxic and safe nanomaterial have shown advantages to be a drug carrier and to modify the targeting group to the targeted therapy. To aim of the study was to explore the effects of MSNs co-loading with 17-allylamino-17-demethoxy-geldanamycin (17-AAG; HSP90 inhibitor) and 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl) phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2; mTOR inhibitor) by targeting vascular endothelial growth factor receptor 2 (VEGFR2) on the viability of human anaplastic thyroid carcinoma FRO cells. The cytotoxicity of 17-AAG and Torin2 were analyzed by MTT assay. The possible synergistic antitumor effects between 17-AAG and Torin2 were evaluated by CompuSyn software. Flow cytometry was performed to assess the VEGFR2 targeting of (17-AAG+Torin2)@ MSNs-anti-VEGFR2 ab and uptake by FRO cells. An ATC xenograft mouse model was established to assess the antitumor effect of (17-AAG+Torin2)@MSNs-anti-VEGFR2 ab in vivo. The results revealed that the combination of 17-AAG and Torin2 inhibited the growth of FRO cells more effectively compared with single use of these agents. Additionally, the synergistic antitumor effect appeared when concentration ratio of the two drugs was 1:1 along with total drug concentration greater than 0.52 µM. Furthermore, in an ATC animal model, it was revealed that the (17-AAG+Torin2)@MSNs-anti-VEGFR2 ab therapy modality could most effectively prolong the median survival time [39.5 days vs. 33.0 days (non-targeted) or 27.5 days (control)]. Compared to (17-AAG+Torin2)@MSNs, the (17-AAG+Torin2)@MSNs-anti-VEGFR2 ab could not only inhibit ATC cell growth but also prolong the median survival time of tumor-bearing mice in vivo and vitro more effectively, which may provide a new promising therapy for ATC.

show abstract

“…Span 60, Tween 60, PEG-600 ART MCF-7; Breast cancer 4-fold higher cytotoxic activity than free ART 2014 [193] Span 60, CHOL Artemisone A-375; Melanoma Highly selective cytotoxicity towards melanoma cells, not to normal skin cells 2015 [194] Span, Tween, CHOL AM, Paclitaxel 4T1; Mouse breast cancer Superior tumor necrosis and smaller tumor volume than free AM 2020 [195] Arrow "↑" indicates an enhancing effect or upregulation; "↓" indicates a diminishing effect or downregulation.…”

Section: Niosomesmentioning

confidence: 99%

“…Asgharkhani et al prepared the ART-loaded niosomes by a certain ratio of Span-60:Tween-60:PEG-600:ART, showing better inhibitory effects to MCF-7 cell line (one-fourth IC 50 compared to free ART) [193]. Compared to free artemether, artemether-loaded nanoniosomes induced more tumor necrosis and inhibited tumor growth in a 4T1-bearing mouse model [195]. Artemisone, a 10-amino-artemisinin derivative of ART, was packed into niosomes to test the inhibitory effects on the melanoma A-375 cell line.…”

Section: Other Types Of Art-type Drugs-loaded Nanocarriersmentioning

confidence: 99%

Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery

et al. 2022

View full text Add to dashboard Cite

Artemisinin, the most famous anti-malaria drug initially extracted from Artemisia annua L., also exhibits anti-tumor properties in vivo and in vitro. To improve its solubility and bioavailability, multiple derivatives have been synthesized. However, to reveal the anti-tumor mechanism and improve the efficacy of these artemisinin-type drugs, studies have been conducted in recent years. In this review, we first provide an overview of the effect of artemisinin-type drugs on the regulated cell death pathways, which may uncover novel therapeutic approaches. Then, to overcome the shortcomings of artemisinin-type drugs, we summarize the recent advances in two different therapeutic approaches, namely the combination therapy with biologics influencing regulated cell death, and the use of nanocarriers as drug delivery systems. For the former approach, we discuss the superiority of combination treatments compared to monotherapy in tumor cells based on their effects on regulated cell death. For the latter approach, we give a systematic overview of nanocarrier design principles used to deliver artemisinin-type drugs, including inorganic-based nanoparticles, liposomes, micelles, polymer-based nanoparticles, carbon-based nanoparticles, nanostructured lipid carriers and niosomes. Both approaches have yielded promising findings in vitro and in vivo, providing a strong scientific basis for further study and upcoming clinical trials.

show abstract

Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer

Cited by 32 publications

References 44 publications

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2

Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery

Contact Info

Product

Resources

About